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Abstract
Background: One in three women who have a prolapse operation will go on to have another operation, though
not necessarily in the same compartment. Surgery can result in greater impairment of quality of life than the
original prolapse itself (such as the development of new-onset urinary incontinence, or prolapse at a different site).
Anterior and posterior prolapse surgery is most common (90 % of operations), but around 43 % of women also
have a uterine (34 %) or vault (9 %) procedure at the same time. There is not enough evidence from randomised
controlled trials (RCTs) to guide management of vault or uterine prolapse. The Vault or Uterine prolapse surgery
Evaluation (VUE) study aims to assess the surgical management of upper compartment pelvic organ prolapse (POP)
in terms of clinical effectiveness, cost-effectiveness and adverse events.
Methods/design: VUE is two parallel, pragmatic, UK multicentre, RCTs (Uterine Trial and Vault Trial). Eligible for
inclusion are women with vault or uterine prolapse: requiring a surgical procedure, suitable for randomisation and
willing to be randomised. Randomisation will be computer-allocated separately for each trial, minimised on:
requiring concomitant anterior and/or posterior POP surgery or not, concomitant incontinence surgery or not, age
(under 60 years or 60 years and older) and surgeon. Participants will be randomly assigned, with equal probability
to intervention or control arms in either the Uterine Trial or the Vault Trial. Uterine Trial participants will receive
either a vaginal hysterectomy or a uterine preservation procedure. Vault Trial participants will receive either a
vaginal sacrospinous fixation or an abdominal sacrocolpopexy. Participants will be followed up by postal
questionnaires (6 months post surgery and 12 months post randomisation) and also reviewed in clinic 12 months
post surgery. The primary outcome is the participant-reported Pelvic Organ Prolapse Symptom Score (POP-SS) at
12 months post randomisation.
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Discussion: Demonstrating the efficacy of vault and uterine prolapse surgeries is relevant not only to patients and
clinicians but also to health care providers, both in the UK and globally.
Trial registration: Current controlled trials ISRCTN86784244 (assigned 19 October 2012), and the first subject was
randomly assigned on 1 May 2013
Keywords: Uterine, Vault, Prolapse, Hysterectomy, Suspension, Symptoms, Randomised controlled trial
Abbreviations: AE, Adverse event; BSUG, British Society of Urogynaecology; POP-Q, Pelvic Organ Prolapse
Quantification; POP-SS, Pelvic Organ Prolapse Symptom Score; PROSPECT, PROlapse Surgery: Pragmatic Evaluation
and randomised Controlled Trials; QALY, Quality-adjusted life year
Background
The reasons for the trial (see also Additional file 1 for
further background):
Gynaecologists have recognised for some time that
both anatomical failure and recurrence of prolapse
symptoms after surgery are common: one in three
women who have a prolapse operation will go on to have
another, though not necessarily in the same compart-
ment [1]. More recently, it has also been recognised that
surgery can be followed by a greater impairment of qual-
ity of life than from the original prolapse itself (e.g. the
development of new-onset urinary incontinence after
surgery, or prolapse at a different site). While anterior
and posterior prolapse surgery is most common (90 % of
operations), around 43 % of women also have a uterine
(34 %) or vault (9 %) procedure at the same time. In-
deed, this demonstrates that women who have a hyster-
ectomy have around a 27 % chance of needing a
subsequent vault prolapse repair.
These data are derived from the first 700 women re-
cruited in PROSPECT (PROlapse Surgery: Pragmatic
Evaluation and randomised Controlled Trials in women
with anterior or posterior pelvic organ prolapse), a large
HTA-funded UK randomised controlled trial (RCT) of
anterior or posterior prolapse surgery with or without
the use of mesh (HTA No. 07/60/18) also being
undertaken by the research team. VUE is a follow-on
trial in which women will be randomised to different
surgical options for upper compartment prolapse
(vault and uterine). This protocol sets out our plans
for running VUE.
Our aim is to identify the optimal surgical procedures
for women with a vault or a uterine prolapse, which will
provide women with the best symptomatic cure and
lowest adverse effect and reoperation rates. Given the
number of prolapse procedures currently performed and
the anticipated rise in the need for such surgery with an
ageing population, [2] the potential cost implications for
the health service are considerable. The findings will
guide gynaecologists in their surgical practice and pur-
chasers in their choice of provision of health care. The
study aims to identify which procedures are not only
most clinically effective but also most cost-effective.
Summary of evidence base
Systematic reviews have demonstrated that there was
not enough evidence to guide practice for women con-
templating surgery for their vault or uterine prolapse
[3, 4]. The trials for vault surgery were individually too
small to be conclusive and, hence, guide practice. Three
RCTs broadly addressed hysterectomy versus uterine
preservation approaches, but differences in the ap-
proaches and techniques used, and the outcome mea-
sures reported, precluded any useful meta-analysis or
conclusions. Thus, there is no reliable evidence to guide
women and their gynaecologists in choosing the best
surgical cure for vault or uterine prolapse.
Implications for proposed project
There is insufficient information about any of the surgi-
cal options to guide management of vault or uterine
prolapse in women. We have identified, from PRO-
SPECT and Health Episode Statistics (HES) data that
around a third of women with prolapse have a hysterec-
tomy for uterine prolapse. At least 25 % (HES data [2])
and 27 % (PROSPECT data) of these women go on to
have a subsequent vault prolapse procedure. The evi-
dence base for treating either of these groups of women
is clearly inadequate, with very little evidence regarding
subjective prolapse symptoms, effect on quality of life,
cost-effectiveness and safety.
This study will fulfil the research need identified by
the Cochrane review [3] and the Interventional Proce-
dures (IP) review [4] for adequately powered RCTs of
the surgical options for women having vault or uterine
prolapse surgery. It will comprise two of the largest,
rigorous and independent RCTs comparing traditional
prolapse operations with each other. We will take into
account the different clinical characteristics of women
having concomitant procedures such as anterior or
posterior repair, or incontinence surgery, and identify
confounding factors which may predict outcomes.
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Choice of comparators
Uterine Trial
The two options for uterine prolapse concern removal
or retention of the uterus. There are a number of surgi-
cal approaches to both options (vaginal, open abdominal,
laparoscopic, robotic laparoscopic) and for pragmatic
reasons we intend to allow surgeons to choose the tech-
niques which they routinely use, within certain broad
categories. This will allow the maximum number of
gynaecologists to recruit to VUE.
Vault Trial
The two broad approaches to vault suspension are vagi-
nal or abdominal. There is a general clinical opinion that
the vaginal approach has a higher recurrence rate but it
is simpler to perform and has less morbidity, but there is
no good evidence to underpin this. Again there are dif-
ferent techniques to both approaches, and we intend to
allow gynaecologists to use their preferred operations,
again within certain broad categories.
These comparators will be further debated within the
clinical and research community through the Research
Committee of the British Society of Urogynaecology
(BSUG) with the aim that VUE will be adopted by the
Society.
Principal objectives
The two parallel trials will compare:
Uterine Trial: in women having uterine prolapse
surgery, the effects of removal of the uterus versus
uterine preservation
Vault Trial: in women having vault prolapse surgery,
the effects of a vaginal vault suspension versus an
abdominal vault suspension
The primary objective is to determine the optimal surgi-
cal management for women with upper compartment
(vault or uterine) pelvic organ prolapse in terms of clinical
effectiveness, cost-effectiveness and adverse events (AEs).
Secondary objectives
1. To determine the differential effects on other
outcomes such as urinary, sexual and bowel
function, quality of life, general health, need for
secondary surgery and adverse effects
2. To identify possible effect modifiers (e.g. concomitant
procedures, age, complex prolapse types)
Methods/design
VUE comprises two parallel, multicentre, RCTs of sur-
gery for women with vault or uterine prolapse. The trial
flow diagram is presented in Fig. 1.
Women considered for trial entry
The study will involve women who are having prolapse
surgery for vault or uterine prolapse. Two parallel but
separate trials will be conducted.
A. Uterine Trial for women with a uterine prolapse:
Experimental: uterine preservation (vaginal
sacrospinous fixation of uterus with sutures or
mesh, or open abdominal or laparoscopic
sacrohysteropexy with a mesh bridge).
Control (standard): vaginal hysterectomy, with a
prespecified vault suspension technique using
sutures or mesh if necessary
B. Vault Trial for women with a vault prolapse;
Control (standard): vaginal sacrospinous fixation
(with sutures or mesh or a mesh kit).
Experimental: abdominal sacrocolpopexy (open
abdominal or laparoscopic, with a mesh bridge)
Permitted concomitant procedures are:
1. Anterior and/or posterior repair,
2. Enterocele repair and
3. Continence procedure (e.g. mid-urethral sling,
colposuspension)
The operations selected for VUE are described in
more detail in Additional file 1.
Divergence from prespecified choices will be docu-
mented with reasons. All other operative variables will
be described using standardised data collection forms.
The exact surgical options will be agreed and standar-
dised by consensus with the Research Committee of
BSUG before the trial begins.
Problems with compliance
We feel that the noncompliance rate amongst gynaecol-
ogists will be low because we will recruit gynaecologists
who are uncertain about which operation to choose for
their patients, and who are motivated to help with re-
search to establish the answer.
We found that the women recruited to PROSPECT
were particularly well-motivated to participate in the
study: only 8.1 % declined to be recruited, 86.9 % have
attended for outpatient review and there is, so far, a
94.9 % response rate to the primary outcome at
12 months.
Inclusion criteria:
 Women with vault or uterine prolapse requiring a
surgical procedure
 Women who are suitable for randomisation
(gynaecologist’s view, i.e. not meeting exclusion
criteria)
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 Women who are willing to be randomised (woman’s
view)
Exclusion criteria (women who are unwilling, unable
or unsuitable to be randomised):
 Previous subtotal hysterectomy
 Previous cervical amputation (Manchester repair)
 Potential future pregnancies
 Comorbidity necessitating particular approach
(e.g. fibroids, previous abdominal surgery
(scarring/adhesions))
 Comorbidity precluding randomisation (e.g. poor
anaesthetic risk)
 Obesity precluding abdominal approach (except if
two vaginal approaches are feasible)
 Colpocleisis (vaginal closure operation)
Identification and enrolment of potential participants
All women listed for vault or uterine prolapse surgery
will be identified by their treating gynaecologist and a
dedicated research nurse in each centre over the 2-year
recruitment period. A log will be maintained of all
women meeting the eligibility criterion (listed for vault
or uterine prolapse surgery), describing reasons if they
do not enter the study. Every woman will be allocated a
unique Study Number.
Local procedures at the participating hospitals are dif-
ferent and the timing and mode of approach to women
and the consent process will vary to accommodate both
the variability at the sites and the needs of the women.
Each eligible woman will be given or sent a Patient In-
formation Leaflet describing the study, a customised
Surgical Information Sheet, a baseline questionnaire and
a Consent Form. Each woman will have the opportunity
Fig. 1 Flow diagram of study design and schedule. POP-SS (Pelvic Organ Prolapse Symptom Score), POP-Q (Pelvic Organ Prolapse Quantification)
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to discuss the study with her gynaecologist. Women will
also have the opportunity to discuss all aspects of the
study with the local clinical team (staff at preadmission
clinics and ward staff while admitted), the research
nurse, family and friends and, if appropriate, with their
GP before admission. Women may make a decision to
participate during a consultation with their gynaecolo-
gist, during a visit to hospital (e.g. when they attend a
clinic appointment, when they attend for preassessment
or when they are admitted for surgery), or alternatively
at home. If the woman agrees to be contacted at home
(recorded on the Surgical Assessment Form), she may
receive a telephone call from the local research nurse to
discuss any queries. Women who decide to participate
following telephone counselling can either send their
completed documents (Consent Form and baseline
questionnaire) through the post to the local team at
their treating hospital or bring it with them if they are
returning to hospital for another consultation or surgery.
Each woman will be asked for her signed informed
consent to be randomised and followed up after her pro-
lapse surgery by postal questionnaires and an examination
in the Gynaecology Outpatient Department. The Patient
Information Leaflet and the Consent Form will all refer to
the possibility of long-term follow-up and being contacted
about other prolapse research if the women are willing.
Each GP will be informed about each of their patients
who participate in the study. Hospital staff will be in-
formed about the study by the principal investigator (PI)
and the research nurse so that they can answer queries
from participants and their relatives.
All women who enter the study will be assigned a
Study Number, complete a baseline questionnaire includ-
ing measurement of prolapse, bowel, urinary, vaginal and
sexual symptoms, and have an objective prolapse assess-
ment (Pelvic Organ Prolapse Quantification (POP-Q) [5])
carried out by the gynaecologist or the research nurse.
Women who consent will be randomised into one of the
trial arms appropriate for her type of prolapse. Random-
isation will be carried out as close to the time of surgery
as is practical, taking into account the hospital routines
and timely need for setting up the operating theatre.
All consenting women will be asked to complete the
follow-up questionnaires at 6 and 12 months at home. They
will also have a review appointment with their gynaecologist
at 12 months to evaluate the results of surgery using the
POP-Q examination and identify problems or need for
other treatment. This amounts to considerably more post-
operative surveillance than is available routinely in the NHS,
and should ensure that all women receive optimum care.
Number of centres involved
We aim to recruit women from approximately 40 cen-
tres, many of which also participated in PROSPECT.
Methods to protect against sources of bias
Randomisation (avoiding selection bias)
When contact details, essential baseline information and
confirmation of signed consent are entered into the
Internet-based VUE database, the local researcher will
be able to randomise the woman in the trial for which
she is eligible (see flow diagram, Fig. 1). Randomisation
will be carried out as close to the time of surgery as is
practical taking into account the hospital routines and
time needed for setting up the operating theatre.
Every woman will be logged with the Study Office and
given a unique Study Number. Randomisation will utilise
the existing proven remote automated computer ran-
domisation application at the study administrative centre
in the Centre for Healthcare Randomised Trials (CHaRT,
a fully registered UK CRC Clinical Trials Unit) in the
Health Services Research Unit, University of Aberdeen.
This randomisation application will be available as an
Internet-based service.
Randomisation will be computer-allocated separately
for each trial and minimised on:
 need for a concomitant anterior and/or posterior
POP operation or none
 need for a concomitant incontinence procedure (e.g.
tension-free vaginal tape (TVT)) or not
 age (under 60 years or 60 and older), and
 surgeon
The choice of operations available to randomised
women will be determined by whether they are having
vault or uterine prolapse surgery. The basic criterion for
joining the study is that the gynaecologist must be un-
certain regarding the best operative technique for the
majority of patients, and they must be competent to per-
form the operations to be compared (i.e. be ‘beyond’ the
learning curve).
Ensuring standardisation of intervention and outcome
measurement (avoiding performance bias)
Both specialist urogynaecologists and general gynaecolo-
gists will be eligible for recruiting and randomising
women, thus extending the generalisability of the trial
and the future transfer of skills. All gynaecologists will
be proficient in performing the POP-Q [5] method of
objective quantification of prolapse descent used pre and
postoperatively.
All gynaecologists will complete a Surgical Standard-
isation Form to provide details of their preferred opera-
tive techniques. The gynaecological surgeons who have
agreed to participate in the study have extensive experi-
ence and training in prolapse surgery. Any additional
training required will be conducted by the clinical grant
applicants and will be directed towards ensuring
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standardisation of their existing techniques and outcome
measures.
The research nurses and the surgeons will complete a
Recruitment Officer Case Report Form (ROCRF) (devel-
oped for PROSPECT and to be adapted for VUE) at the
time of surgery to ensure a complete record of all surgi-
cal techniques and materials used and any intraoperative
difficulties or complications. The research nurses in each
centre will ensure completeness and accuracy of data
entry using remote data capture via a study web-based
portal at the Study Office in Aberdeen, authored and
managed by the UK CRC-registered Clinical Trials Unit
in Aberdeen (CHaRT).
As this is a pragmatic trial, postoperative care will be
according to local centre practice but clinical and
resource-use data will be recorded.
Loss to follow-up (attrition bias)
We have used a conservative estimate of 15 % loss to
follow-up in the power calculations. We will take very
active measures to minimise such loss, such as telephon-
ing the women, using retention incentives and checks
with their GPs. In addition we will obtain consent from
the women to enable us to access centrally-held NHS
data, for example, via the NHS Strategic Tracing Service
in England and Wales, and using Community Health
Index (CHI) numbers from the Information Services
Division in Scotland. We have extensive experience of
using such strategies and measures and have received
ethics approval to do so in previous studies.
Other sources of bias (detection bias)
Group allocation will be concealed from the woman and
the ward staff if clinically possible, although blinding in
theatre is not possible given that this is a surgical trial.
However, we do not feel that it is necessary or ethical to
perform sham incisions to conceal the route of surgery.
Outcome assessment is largely by participant self-
completed questionnaire, so avoiding interviewer bias.
However, the clinical review at 12 months in the Outpa-
tients Department (secondary outcome) will be con-
ducted by staff blinded to allocation by performing the
POP-Q examination, without knowledge of the actual
procedure performed when possible. Participants will
undergo an objective vaginal POP-Q assessment before
the group allocation is revealed. Women and research
staff will not be explicitly informed of which operation
was randomly selected, although examination may reveal
which operation was actually carried out, and women
will be told if they wish to know.
Research staff who are blinded to allocation will con-
duct the data collection, data entry and analysis using
Study Numbers only to identify women and question-
naires. All women will be actively followed up, with
analysis based on the intention-to-treat principle. All
analyses will be clearly predefined to avoid bias, and will
be rehearsed in PROSPECT to ensure compatibility of
results.
Original sample size
In the Uterine Trial, 268 women in each arm would be
required to achieve 90 % power to detect a difference in
the primary outcome measure (i.e. POP-SS [6, 7] at
1 year following surgery) of 0.28 of a standard deviation
at a significance level of 5 % (two-sided alpha). Allowing
for 15 % loss to follow-up at 1 year would require 315 to
be recruited to each arm (630 in total). The accumulat-
ing PROSPECT data indicate that a conservative esti-
mate of the standard deviation of the primary outcome
is 7 units and a difference in means of 2 units would
represent a clinically important difference in POP-SS
[6, 7]. Therefore, a standardised effect size of 2/7 = 0.28
standard deviations (SDs) is used.
A smaller number of women would be expected to be
recruited to the Vault Trial. Using data from the women
recruited to PROSPECT to date with vault or uterine
prolapse, the expected number of recruits to the Vault
Trial can be estimated at 27 % of that recruited to the
Uterine Trial. Therefore, in the time that 630 women
could be recruited to the Uterine Trial, an expected 85
women would be recruited to each arm of the Vault
Trial (170 in total). A trial of 170 would have 80 %
power to detect a difference of 0.43 SDs at a 5 % signifi-
cance level (two-sided alpha). A standardised effect size
of 0.43 equates to a difference in means of 3 units in the
POP-SS measure.
In total, based on these assumptions, the number of
recruits required across both trials would be 800
women.
PROSPECT data show that the mean monthly number
of women randomised is 2.2 per centre and that 39 % of
anterior/posterior prolapses, 259/(405 + 259) (Additional
file 1) required concomitant upper vaginal prolapse sur-
gery. Given that PROSPECT has the same inclusion cri-
teria as this study and assuming that randomisation
rates will be the same as in PROSPECT, a centre can be
expected to recruit 0.86 women per month from those
who would previously have been randomised in PRO-
SPECT. PROSPECT data also show that 7 % of women
presenting with vaginal prolapse require upper compart-
ment surgery only – these women are not eligible for
randomisation in PROSPECT, but would be eligible to
be randomised in VUE. Assuming that randomisation
rates are the same in this group of women, the expected
monthly recruitment can, therefore, be inflated to 0.93
per site, i.e. 0.73 for the Uterine Trial and 0.2 for the
Vault Trial. In order to recruit 630 women to the Uter-
ine Trial and 170 to the Vault Trial, 40 centres will need
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to be recruited over twenty-four calendar months,
allowing for a staggered start. The trial inception will
be in the three centres led by the coapplicants, with
recruitment subsequently rolling out to the other
centres.
Recruitment extension and increase in Vault Trial sample
size
At steady state, recruitment rate of the Uterine Trial was
assumed to be approximately 29 women per month. Re-
cruitment has been slower than anticipated, and is cur-
rently averaging 15 per month. Reasons for lower
recruitment include women’s preference (particularly for
a hysterectomy) and lower than anticipated consent
rates (around 30 % of those approached to participate in
the Uterine Trial consent to do so, compared to the
50 % anticipated). As a result, an extension to the re-
cruitment phase (an additional 15 months) is necessary
to achieve the original target sample size (630).
PROSPECT data showed that the number of women
requiring vault repair is approximately 27 % of the num-
ber presenting with uterine prolapse. Therefore, during
the original time period for randomising 630 women to
the Uterine Trial, it was anticipated that a further 170
women requiring vault repair would also be randomised
to the Vault Trial.
Recruitment rates to the Vault Trial are in line with
original predictions. With an additional 15 months of
recruitment, the Vault Trial will continue to recruit
beyond the original sample size of 170.
Conservatively assuming an average of 7 women ran-
domised per month, we project a revised total of 280
Vault Trial participants may be recruited, which is 140
per arm or 119 allowing for 15 % loss to follow-up. This
would give 80 % power to detect a difference of 0.36
SDs at 5 % significance level (two-sided alpha). A stan-
dardised effect size of 0.36 SDs equates to a difference in
means of 2.5 units in the primary outcome (POP-SS),
considering a SD of 7. This is a smaller difference than
originally calculated (i.e. 3 units, with 80 % power). This
also equates to a relative reduction in the width of the
confidence interval of 22 % when compared to the preci-
sion without the extension. As the POP-SS at baseline is
higher in women with vault prolapse (15.2 versus 12.0 in
women with a uterine prolapse, data from PROSPECT)
we could reasonably expect a greater difference after
surgery.
It is anticipated that 1820 eligible women will need to
be screened in order to achieve the recruitment rates re-
quired (Table 1).
Subsequent arrangements
Informing key people
Following formal trial entry:
The Study Office will inform the woman’s GP (by let-
ter enclosing information about VUE and Study Office
contact details).
The local research nurse will:
1. File the hospital copy of the Consent Form in the
hospital notes along with information about VUE
and the POP-Q measurements
2. Inform the ward and theatre staff as appropriate of
the woman’s entry to the study and details of the
intervention allocation (theatre only)
3. Use the VUE Internet database to enter data
regarding the participant, including data required to
complete randomisation; and intraoperative and
postoperative information abstracted from local
medical records
4. Return all study documentation to the Study Office
in Aberdeen after database entry of essential data
Monitoring the women
Women will be contacted by telephone, post or email as
appropriate. In case of nonreturn of questionnaires, or
nonattendance at outpatient appointments, attempts will
be made by staff at the Study Office to trace the women
directly using these means or indirectly by contacting
the GP.
Table 1 Recruitment numbers expected
Uterine Trial
N = 630
Vault Trial
N = 280
Women needed per arm (minimum) 268 140
Allowing for 15 % dropout 315 119
Total number of women 630 280
Assuming 50 % willing to enter RCT, number of women having prolapse surgery needed 1260 560
Number of operations per year per typical centre 18 5
Number of typical centres needed for approx 39 months 35 34
Allowing for a staggered start 40 40
RCT randomised controlled trial
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Notification by GPs
GPs are asked to contact the Study Office if one of the
participants moves, becomes too ill to continue or dies,
or any other notifiable event or possible serious adverse
event (SAE) occurs. Alternatively, staff at the Study
Office may contact the GP.
Offices for National Statistics (HES data in England, ISD
data in Scotland)
Consent will be sought from all women to trace their
medical records and addresses from local records and
centrally held computerised databases. This should
facilitate long-term follow-up.
Ethical arrangements
We believe that the proposed research does not pose
any specific risks to individual participants nor does it
raise any extraordinary ethical issues.
Data collection and processing
Follow-up will continue for 12 months from the date of
randomisation (Table 2). It is not part of this protocol or
the current study to follow up the women beyond this
time. However, consent will be sought to make this pos-
sible in the future, and long-term follow-up is planned
(Additional file 2, Protocol for long-term follow-up).
Proposed outcome measures
The outcomes are identical to those piloted and used
successfully in PROSPECT. We are using standardised
outcome instruments developed by the International
Consultation on Incontinence (ICI) [8] for urinary,
bowel and vaginal symptoms, and will conform to the
International Continence Society (ICS) recommenda-
tions for terminology and standard techniques [9]. We
have liaised with our consumer advisor (IM) to ensure
that all relevant issues are covered, the patient
information and survey instruments are acceptable to
the women and the outcome measures relevant.
Use of prolapse severity score as primary outcome
Traditionally, the primary outcome of prolapse surgery
has been considered to be objective (physical) restor-
ation of normal anatomy, judged usually by the surgeon
performing the operation (clinician observation). This
does not necessarily correlate with women’s subjective
prolapse symptoms, but these have been much more dif-
ficult to measure, not least because they can be multiple,
and cure of one symptom may be accompanied by the
occurrence of new symptoms. However, we strongly feel
that the primary endpoint must depend on the woman’s
symptoms as these alone dictate whether further treat-
ment is requested and required. Hence, as in PRO-
SPECT the primary clinical outcome will be the
subjective difference in severity of prolapse symptoms
measured using the POP-SS [6, 7].
Primary outcomes
1. The primary clinical outcome is women’s prolapse
symptoms measured using the Pelvic Organ
Prolapse Symptom Scale (POP-SS) [6, 7], at 1 year
after randomisation
2. The primary quality of life outcome is the overall
effect of prolapse symptoms on everyday life
3. The primary economic outcome measure of cost-
effectiveness is incremental cost per quality-adjusted
life year (QALY) (QALYs based on the EuroQol five
dimensions questionnaire (EQ-5D) data) [10]
Secondary outcomes
General
 immediate and late postoperative morbidity
 other adverse effects or complications
Table 2 Schedule for assessments/data collection
Assessment Recruitment Intervention
(surgery)
6 months (postal
questionnaire)
12 months (postal
questionnaire)
12 months
(clinic appointment)
Assessment of eligibility criteria Xa
Written informed consent X
Clinical status Xa Xa Xa
Adverse events Xa Xb Xb Xa
Prolapse symptom score
(POP-SS)
Xb Xb Xb
Patient-reported symptoms Xb Xb Xb
Hospital admissions Xb Xb Xa
Health-related quality of life
(EQ-5D)
Xb Xb Xb
Health care utilisation Xb Xb
aCRF; bParticipant questionnaire. EQ-5D EuroQoL five dimensions questionnaire, POP-SS Pelvic Organ Prolapse Score
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 operating time
 blood loss
 number of nights in hospital
 number of readmissions to hospital
 need for further surgery for prolapse or for urinary
incontinence
 time to further surgery
 recommendation to a friend, and
 satisfaction with surgery
Prolapse outcomes
 subjective recurrence of prolapse
 subjective continuation/recurrence of prolapse
symptoms
 objective residual prolapse stage (POP-Q) at original
site
 the development of new (de novo) prolapse at
another site, and
 need for other conservative prolapse treatment (e.g.
pelvic floor muscle training (PFMT), mechanical
device)
Urinary outcomes
 urinary incontinence (persistent or de novo, and types
of incontinence) using the ICI questionnaires [8]
 voiding dysfunction, and
 need for alternative management for incontinence or
voiding dysfunction (e.g. PFMT, mechanical devices,
surgery, drugs, intermittent catheterisation)
Bowel outcomes
 constipation (persistent or de novo), and
 faecal incontinence (persistent or de novo)
Sexual function outcome
 dyspareunia/apareunia/difficulty with intercourse, and
 vaginal symptoms using the ICI-Vaginal Symptoms
Questionnaire [8]
Quality of life outcome measures
 condition-specific quality of life measures, and
 general health measures (EQ-5D) [10]
Economic outcome measures
 cost and use of NHS services
 cost to the women and their families/carers
 QALYs estimated from the responses to the EQ-5D
[10], and
 the incremental costs, QALYs and incremental cost
per QALY derived by the economic model over a
longer-term time horizon
Adverse effects and complications
Complications related to mesh or native tissue will be
recorded and coded using the IUGA/ICS Classification
Systems [11, 12]
Questionnaires and Case Report Forms (CRFs)
Questionnaires for participants
Women will be asked to complete a baseline question-
naire before surgery. Content will include:
1. Prolapse symptoms (POP-SS) [6, 7]
2. EQ-5D [13]
3. Urinary outcome questions (urinary symptoms and
urinary leakage, effect on quality of life [10]
4. Bowel function outcome questions and effect on
quality of life
5. Vaginal and sexual symptoms, effect on quality of
life [10]
The follow-up questionnaire at 6 months will enquire
about:
1. Prolapse symptoms (POP-SS) [6, 7]
2. EQ-5D [13]
3. Readmissions to hospital
The follow-up questionnaire at 12 months will repeat
the baseline questions and in addition will enquire
about:
1. Complications and adverse effects
2. Need for further treatment for prolapse,
incontinence or complications
3. Health care utilisation questions (including GP
consultations and hospital visits/admissions, use of
other services)
4. Personal costs (pad use, catheter use, over-the-
counter medication, other health care services)
5. Satisfaction with results and recommendation to a
friend
Case Report Forms (CRFs)
Baseline/hospital research nurse CRF
At baseline, the research nurse will complete a Case
Report Form with the following content:
Preoperative
1. Contact details, GP address, telephone numbers
2. Gynaecological and obstetric history
3. Measurement of prolapse stage using POP-Q [5]
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4. Planned operative details
Intraoperative
1. Intraoperative data including date of admission and
operation
2. Operative procedures and theatre time
3. Catheter and vaginal pack use
4. Complications
Postoperative
1. Pain relief, laxative use, infection, haematoma, other
complications
2. Return to theatre
3. Date of discharge
12-month clinical review assessment form
At 12 months after surgery, all women will be examined
for:
1. Clinical findings (prolapse stage using POP-Q [5])
2. Complications (e.g. mesh exposure)
Serious Adverse Event (SAE) Report Form
Serious adverse events will be recorded using a standard
SAE CRF form. The SAE form will be used to record de-
tails of any SAEs (see also ‘Safety concerns’). Adverse
events will be categorised using the IUGA/ICS Classifi-
cation of Complications coding systems [11, 12].
HES and ISD data
After the last woman has been recruited, we will run
periodic checks for operations, diagnoses and hospital
admissions with centrally collected data to supplement
and validate data collected from the participants, and to
set up mechanisms for long-term follow-up.
Data processing
Research nurses will enter locally collected data in the
centres. Staff in the Study Office will work closely with
local research nurses to ensure that the data are as
complete and accurate as possible. Follow-up question-
naires to women will be sent from and returned to the
Study Office in Aberdeen. Extensive range and
consistency checks will further enhance the quality of
the data.
Change of status procedures
Participants will remain on the trial unless they chose
not to receive further questionnaires and/or attend clinic
appointments. We will retain their data and their per-
mission to access health care records unless consent for
these activities is explicitly withdrawn.
Analysis plans
Statistical analysis
A single principal analysis is anticipated at 12 months
after the last woman has had her operation. The Data
Monitoring Committee (DMC) will determine the fre-
quency of confidential interim analyses, but at present
these are planned on three occasions during the data
collection period.
All analyses will be based on the intention-to-treat
principle. All outcomes in both trials will be described
with the appropriate descriptive statistics where relevant:
mean and standard deviation for continuous and count
outcomes, or medians and interquartile range if required
for skewed data, numbers and percentages for dichotom-
ous and categorical outcomes (e.g. subjective recurrence
of prolapse).
Analysis of the primary outcome Pelvic Organ Pro-
lapse Symptom Score (POP-SS) will estimate the mean
difference (and 95 % confidence interval) between inter-
vention and control groups at 12 months after random-
isation using a general linear model that adjusts for the
minimisation covariates and other important prognostic
covariates, including the baseline symptom score. A
similar analysis will be used to analyse the primary out-
come at 6 months after surgery.
All secondary outcomes will be analysed in a similar
manner but using the appropriate generalised linear
model (e.g. logistic regression for dichotomous data such
as subjective prolapse failure, Poisson or negative bino-
mial regression for count data such as number of nights
in hospital) or time to event methods (e.g. Cox regres-
sion on time to further surgery) where required. We will
explore analysing outcomes at all time points simultan-
eously using, for example, generalised estimating equa-
tions or generalised linear latent and mixed models with
relevant link functions.
The ways in which these data will be analysed are set
out in the VUE Statistical Analysis Plan and Dummy
Tabulations. All study analyses will be according to a
statistical analysis plan that will be agreed in advance by
the VUE Steering Committee and compatible with that
rehearsed in PROSPECT.
Planned subgroup analyses
Subgroup analyses will be carried out within the follow-
ing groups:
1. Concomitant anterior and/or posterior repair or
none
2. Concomitant continence procedure or not
3. Age (below 60 years or 60 years and older)
Heterogeneity of treatment effects amongst subgroups
will be tested for using the appropriate subgroup by
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treatment group interactions [13]. Stricter levels of stat-
istical significance (2P < 0.01) will be sought, reflecting
the exploratory nature of these analyses.
Methodological analyses
The responses from women and their objective clinical
findings will provide a rich data source for exploration
of the correlation between patient-reported and
clinician-observed outcomes, and between prolapse
symptoms and their effect on quality of life. This meth-
odological research is intended to advance the contro-
versial field of prolapse outcome measurement, and
build upon our existing work in this area.
Proposed frequency of analyses
Women will be followed up at 6 and 12 months after
randomisation. They will be asked to consent to long-
term follow-up although this is not to be funded by this
application. A single main analysis will be performed at
the end of the trial when all 12-month follow-up has
been completed. An independent DMC will review con-
fidential interim analyses of accumulating data at its dis-
cretion but at least annually.
Economic issues
The trial will include a formal economic evaluation
assessing the costs, quality of life and cost-effectiveness
of the interventions compared to the perspective of the
NHS and to the women and their families. Resource-use
data collected will include the cost of the intervention
and the use of primary and secondary NHS services by
the women including referral for specialist management.
Health service costs refer to those incurred directly by
the NHS due to the surgery for uterine and vault pro-
lapse and subsequent appointments and procedures. Per-
sonal costs to the women will also be investigated.
Resource use and costs
Health care resource use will be recorded prospectively
for every patient within the study. For the surgical inter-
ventions, operative details will be recorded at the time of
surgery (e.g. the time the surgery takes, the time spent
in recovery, grade of surgeon and assistant, grade of an-
aesthetist). A parallel exercise will establish resources
used immediately before, during and after (i.e. in recov-
ery) the operation, for example, other staff, consumables
(surgical requisites, mesh), and capital (costs associated
with using the theatre facilities, costs of using reusable
equipment). Costs to the patients will be collected using
a questionnaire based on one developed by the UK
working party on patient costs. The use of secondary
care services (e.g. length of hospital stay, outpatient ap-
pointments, readmission) will be abstracted from patient
notes or questionnaires. The use of primary care
services, including medications will be collected using a
patient questionnaire. Unit costs/prices will be obtained
using published estimates for health care services and/or
interventions.
Self-purchased health care is likely to include items
such as pads bought by the participant, prescription
costs and over-the-counter medications. Information
about these will be collected through the health care
utilisation questions.
Quality of life
A generic instrument (the EQ-5D) [10] will be used to
measure health outcomes. Trial participants will be
asked to complete the EQ-5D at baseline and at 6 and
12 months after their operation and randomisation, re-
spectively. This instrument will provide the quality of life
weights to compute the QALYs.
Cost-effectiveness
Incremental cost-effectiveness ratios will be computed
comparing the cost of the interventions. The difference
in effectiveness will be expressed in terms of the number
of patients cured and number of patients who improve.
These data will be retrieved from the participant ques-
tionnaires. Incremental cost-utility ratios will be com-
puted comparing the interventions. The difference in
utility will be expressed in terms of QALYs. Where ap-
propriate the analysis of incremental costs, effectiveness
and cost-effectiveness will be based on similar statistical
models as those outlined in the statistical analysis above.
Similarly, and where the data allow, the identification of
appropriate subgroups for analysis will be similar to that
of the statistical analysis. This ‘within-trial’ analysis will
include both deterministic and stochastic sensitivity
analyses to explore statistical and other forms (e.g.
around unit costs or the source of utility estimates)
of uncertainty.
Modelling of longer-term outcomes
While the within-study results will prove useful it is im-
portant to note that prolapse is a chronic condition and
the effects of treatment on costs and outcomes may per-
sist into the future. An economic model which considers
a longer-time horizon will be developed to provide add-
itional information for policy-makers. In the model, the
findings of the trial will be extrapolated to the patient’s
lifetime. The model will describe care pathways that
women may follow and will include the initial surgery
and any subsequent treatments. The structure of the
model will be developed in collaboration with clinicians
and trial collaborators. Parameter estimates for relative
effectiveness up to 1 year, costs and utilities will be de-
rived from the trial data. Data from the trial will be sup-
plemented with data from other sources (e.g. Cochrane
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reviews). Estimates of mortality will be based on data
from life tables. Mortality rates will be adjusted, where
necessary, using relative risks of mortality after prolapse
surgery. These data will be obtained from the literature.
These data will be assembled systematically and will fol-
low guidelines for good practice [14].
Outcomes in the model will be expressed in terms of
an incremental cost per QALY. Parameter uncertainty
will be integrated by the incorporation of probability dis-
tributions into the model and involve Monte Carlo
simulation. Other forms of uncertainty such as that as-
sociated with choices made about the structure of the
model, discount rate, etc., will be addressed through sen-
sitivity analysis. The base case and sensitivity analyses
will be presented as cost-effectiveness acceptability
curves (CEACs). Where data allow, the model will be
reestimated for the subgroups identified above for the
within-trial analysis. The model will also be used to
identify priorities for further research by investigating
the expected value of information.
All study analyses, including the within-trial and mod-
elling analyses, will be conducted according to an eco-
nomic analysis plan that will be agreed in advance by
the VUE Steering Committee.
Recruitment rates and milestones
Original recruitment rates
Figure 2 shows the original projected recruitment of
centres and participants, and projected number of
women to be approached. Three centres will be estab-
lished relatively early in the project followed by roll out
to the others over the subsequent months.
The participant recruitment graph in Fig. 2 has been
modelled to take into account: the phased rollout to the
centres over the first 18 months; that there will be lags
between the approach to women when they are in hospital
for preassessment and their admission for operation; and
that there are likely to be fewer operations around August
and over Christmas (due to holidays).
Revised recruitment rates with extension
Due to the slower than anticipated recruitment in the
Uterine Trial a 15-month extension has been approved
by the TSC and DMC oversight groups and funder
(February 2015). The Uterine Trial is currently aver-
aging 15 randomised participants per month. The Vault
Trial will continue to recruit (beyond the original tar-
get) during this extension. A revised recruitment graph
detailing changes to both the Vault and Uterine Trials
is shown in Fig. 3.
In summary, we aim to recruit 910 women to the ran-
domised trials (630 to the Uterine Trial and 280 to the
Vault Trial).
Organisation
It is anticipated that there will be 3-monthly project
management meetings, five meetings of the Steering
Committee and four of the DMC. Two meetings are
planned for collaborators (including gynaecologists, local
research nurses, consumer participants and members of
BSUG), the first is timed to occur when all the sites have
been identified and the second when the results are
available.
These time-related milestones will be used to enable
close monitoring of progress.
Local organisation in centres
1. Lead gynaecologist (local PI)
Each collaborating centre will identify a lead
gynaecologist who will be the point of contact for
that centre. The responsibilities of this person will
be to:
 establish the study locally (e.g. by obtaining
agreement from clinical colleagues; facilitate local
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regulatory approvals; identify, appoint and train a
local research nurse; and inform all relevant local
staff about the study (e.g. other consultant
gynaecologists, junior medical staff, secretaries,
ward staff ))
 take responsibility for clinical aspects of the study
locally (e.g. if any particular concerns occur)
 identify which RCT the woman is eligible to
participate in (vault or uterine), explain the
different surgery options to them, and ensure that
study documentation has been provided and that
informed consent has been obtained
 notify the Study Office of any unexpected clinical
events which might be related to study
participation
 provide support, training and supervision for the
local research nurse(s)
 represent the centre at the collaborators’
meetings
2. Local research nurse
Each collaborating centre will appoint a local
research nurse to organise the day-to-day recruit-
ment of women to the study. The responsibilities of
this person will be to:
 keep regular contact with the local lead
gynaecologist, with notification of any problem or
unexpected development
 maintain regular contact with the VUE Study
Office
 keep local staff informed of progress in the study
 contact potential participants by: providing the
Patient Information Sheet to women being
admitted electively for prolapse surgery;
identifying any eligible women at preassessment
clinics or on the ward while they are in hospital
for their prolapse surgery; explain the study and
the potential for participation in a trial if they are
eligible; explaining what is intended by research
access to their NHS data; and describing the
possibility of long-term follow-up and participa-
tion in other research
 obtain the woman’s written consent
 keep a log of whether eligible women are
recruited or not (with reasons for
nonparticipation)
 collect baseline data describing the women, log
this information in the web-based VUE database
and send paper copies to the Study Office along
with the original signed Consent Forms
 use this information to randomise the women
using the web-based VUE database
 ensure operative and postoperative data are
collected and recorded in the web-based VUE
database, and send paper copies to the Study
Office
 file relevant study documentation (e.g. Consent
Forms, POP-Q results) in the woman’s medical
records
 organise and supervise alternative recruiters in
case of holiday or absence
 Revised projected recruitment chart
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 represent the centre at the collaborators’
meetings
Study coordination
The Study Office team
The Study Office is in CHaRT, Health Services Research
Unit in Aberdeen and provides day-to-day support for
the clinical centres. It is responsible for all data collec-
tion (such as mailing questionnaires), follow-up, data
processing and analysis. It is also responsible for provid-
ing and maintaining the randomisation service, and
communicating with the sites about VUE-specific issues.
We will produce a yearly VUE newsletter for partici-
pants and collaborators to inform everyone of progress
and maintain enthusiasm.
The VUE Study Office Team (Aberdeen-based grant
holders and Study Office members) will meet formally at
least monthly during the course of the study to ensure
smooth running and trouble-shooting.
The Project Management Group (PMG)
The study is supervised by its PMG. This consists of the
grant holders and representatives from the Study Office.
Observers may be invited to attend at the discretion of
the PMG. We plan to meet or hold a teleconference
every 3 months on average.
The Trial Steering Committee (TSC)
The study is overseen by an independent Trial Steering
Committee (TSC). The membership comprises the four
independent members (including the chair), the chief in-
vestigator (CI) and grant holders. Observers or members
of the sponsors (University of Aberdeen and NHS
Grampian) and the funders (the HTA) may also attend,
as may other members of the VUE Study Office or
members of other professional bodies at the invitation of
the chair. It is anticipated that the TSC will meet on five
occasions.
Research governance
The trial will be run under the auspices of CHaRT based
at the Health Services Research Unit, University of
Aberdeen. This will ensure compliance with research
governance, and provide centralised trial administra-
tion, database support and economic and statistical
analyses. CHaRT is a registered Clinical Trials Unit
with particular expertise in running multicentre RCTs
of complex and surgical interventions.
The CI will ensure, through the TSC, that adequate
systems are in place for monitoring the quality of the
study (compliance with Good Clinical Practice (GCP))
and appropriate expedited and routine reports of adverse
effects, to a level appropriate to the risk assessment of
the study.
Data protection
The trial will comply with the Data Protection Act 1998 and
regular checks and monitoring are in place to ensure com-
pliance. Data are stored securely in accordance with the Act
and archived to a secure data storage facility. The Consent
Form will state that other researchers may wish to access
(anonymised) data in the future. The senior IT manager (in
collaboration with the trial statistician) will manage access
rights to the data set. Prospective new users must demon-
strate compliance with legal, data protection and ethical
guidelines before any data are released. We anticipate that
anonymised trial data will be shared with other researchers
to enable international, prospective meta-analyses.
Sponsorship
The study is cosponsored by the University of Aberdeen
and NHS Grampian.
Retention of data
It is intended to follow up the whole cohort of women
for at least 10 years, and data will be retained as long as
necessary for this purpose. Permissions will be sought
from the relevant research governance bodies and the
Ethics Committee. Attention has recently been drawn to
the importance of long-term follow-up, especially in the
study of pelvic floor dysfunction [15].
Data and safety monitoring
Data Monitoring Committee
A separate and independent Data Monitoring Committee
(DMC) will be convened. It is anticipated the members
will meet once to agree terms of reference and on at least
three further occasions to monitor accumulating data and
oversee safety issues. This committee will be independent
of the study organisers and the TSC. During the period of
recruitment to the study, interim analyses will be supplied,
in strict confidence, to the DMC, together with any other
analyses that the committee may request. This may in-
clude analyses of data from other comparable trials. In the
light of these interim analyses, the DMC will advise the
Steering Committee if, in its view:
1. One of the methods of prolapse surgery has been
proved, beyond reasonable doubt, to be different
from the control (standard management) for all or
some types of women (in respect of either
effectiveness or unacceptable safety concerns)
2. The evidence on the economic outcomes is
sufficient to guide a decision from health care
providers regarding recommendation of which
operation to choose
The TSC can then decide whether or not to modify in-
take to the trial. Unless this happens, however, the TSC,
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PMG, clinical collaborators and Study Office staff (ex-
cept those who supply the confidential analyses) will
remain ignorant of the interim results.
The frequency of interim analyses will depend on the
judgement of the chair of the DMC. However, we antici-
pate that there might be two interim analyses and one
final analysis.
The chair and the other independent members are to
be appointed after confirmation by the HTA.
Safety concerns
The VUE trial involves surgical operations for prolapse
which are well-established in clinical practice. Adverse
effects may occur after any type of prolapse surgery. The
relevant guidelines for reporting SAEs will be followed.
Collaborators and participants may contact the chair of
the TSC through the Study Office about any concerns they
may have about the study. If concerns arise about proce-
dures, participants or clinical or research staff (including
risks to staff) these will be relayed to the chair of the DMC.
Safety - definitions
An adverse event (AE) is defined as any untoward med-
ical occurrence in a participant, not necessarily having a
causal relationship.
All related SAEs and AEs will be recorded. Unrelated
SAEs or AEs will not be recorded.
Within VUE, an SAE or AE is defined as ‘related’ if it
occurs as a result of a procedure required by the proto-
col (i.e. prolapse surgery), whether or not this procedure
is the specific intervention under investigation and
whether or not it would have been administered outside
the study as normal care.
Adverse events are not signs or symptoms of the dis-
ease being studied (in this case uterine or vault
prolapse).
An AE is defined as ‘serious’ (SAE) if it:
 results in death
 is life-threatening
 prolongs inpatient hospitalisation*
 requires hospitalisation*
 results in persistent/significant disability/incapacity,
or
 is otherwise considered medically significant by the
investigator
*Hospitalisation is defined as any overnight hospital
admission or day-case admission.
Adverse events which are expected after prolapse sur-
gery are listed below. Any AEs which are deemed to be
related and serious but unexpected (i.e. not on the list
below) will require expedited onward reporting to the
sponsor.
Expected adverse events
In this study the following AEs are potentially expected:
Possible (expected) AEs during or associated with sur-
gery are:
 injury to organs, blood vessels or nerves
 excess blood loss
 blood transfusion; anaesthetic complications
 death
Possible (expected) AEs following surgery are:
 excess blood loss
 haematoma
 blood transfusion
 bowel obstruction
 constipation
 faecal incontinence
 thrombosis/deep venous thrombosis/pulmonary
embolism
 urinary tract infection; wound infection
 other infection (sepsis, septicaemia, abscess)
 vaginal adhesions
 pain (acute or chronic, e.g. pelvic pain/buttock pain/
sciatica)
 new or persistent sexual problems including pain
(dyspareunia) and inability to have intercourse
(apareunia)
 perineal scarring/tightness requiring surgery (e.g.
Fenton’s procedure)
 urinary retention/voiding difficulties (requiring
conservative intervention, e.g. indwelling or
intermittent catheterisation, drugs)
 urinary retention/voiding difficulties requiring
surgical intervention (e.g. loosening/division of tape)
 new or persistent lower urinary tract symptoms (e.g.
urinary incontinence, overactive bladder)
 granulation tissue (including related discharge or
bleeding)
 skin tag or skin bridge
 mesh exposure/extrusion which requires no
treatment or conservative treatment in clinic only
(e.g. trimming, local oestrogens, silver nitrate,
antibiotics)
 mesh exposure/extrusion requiring hospitalisation
for surgical removal of part or all of the mesh
 other mesh complications (e.g. clumping); suture
removal/trimming
 death
Recording and reporting AEs and SAEs in VUE
Recording AEs in VUE
Within VUE, all related AEs and SAEs will be recorded
on the Serious Adverse Event Form, CRF or participant
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questionnaires. In addition all deaths for any cause
(related or otherwise) will be recorded on the Serious
Adverse Event Form. All SAEs will be confirmed by
the local PI.
Reporting responsibilities of the CI
When the SAE form is uploaded onto the trial website,
the CI or trial manager will be automatically notified.
The CI (or trial manager) will report any serious and re-
lated and expected (i.e. listed above) SAEs to the sponsor
within 14 days of receiving the SAE notification.
If, in the opinion of the local PI and the CI, the event
is confirmed as being serious and related and unex-
pected (i.e. not listed above), the CI or trial manager will
notify the sponsor within 24 hours of receiving the SAE
notification. The sponsor will provide an assessment of
the SAE. The CI (or trial manager) will report any
serious and related and unexpected SAEs to the main
REC and the DMC within 15 days of the CI becoming
aware of it.
All related SAEs will be summarised and reported to
the Ethics Committee, the funder and the TSC in their
regular progress reports.
Ethical issues and arrangements
The North of Scotland Research Ethics Committee 2 has
reviewed this study. The study will be conducted ac-
cording to the principles of good practice provided by
Research Governance Guidelines. We believe that this
study does not pose any specific risks to individual
participants beyond those of any surgery, nor does it
raise any extraordinary ethical issues.
Risks and benefits
The benefit to the women participating in the trial is the
chance of receiving the optimum treatment for that con-
dition, although we do not know what that treatment is.
The risks are that they may have a suboptimal operation,
but any operation carries a risk and it is not known
which is optimal or more risky. The benefit to women,
the NHS and society is that at the end of the trial it will
be known which operations are most effective and cost-
effective.
Information about risks and benefits and informed
consent
Women will be informed of possible benefits and known
risks of participation in the trials by means of a Patient
Information Leaflet, discussion with the local research
nurses and their own consultant gynaecologist. Women
will be having prolapse surgery anyway, and we do not
anticipate that they will run additional risks by partici-
pating in the trial. They will sign a Consent Form ap-
proved by the Ethics Committee. They will be consented
to participating in the study with follow-up, being ran-
domised, being contacted in the future about this and
other research including electronic tracing using NHS
data, and data linkage with computerised NHS data
sources. Women who are not able or not willing to be
randomised will not be recruited.
A standardised Surgical Information Sheet, similar to
that in use in PROSPECT and using new Patient Infor-
mation Sheets produced by the BSUG, will be adapted
to provide specific clinical information for women about
uterine and vault surgical options, including known
complications.
Satellite studies
It is recognised that the value of the study will be en-
hanced by ancillary studies of specific aspects. Plans for
some of these may be submitted to other grant funding
bodies. Suggestions will be discussed and agreed in ad-
vance with the TSC and also agreed with the NETSCC
HTA. Appropriate legislative approvals will be sought
for any new proposals.
Indemnity
The Patient Information Leaflet provides the following
statement regarding indemnity for negligent and non-
negligent harm:
‘We do not expect any harm to come to you by taking
part in this study. All the materials and techniques are
already being used in the NHS for prolapse surgery.
Your participation in the study is therefore only to help
us evaluate these procedures and should not involve any
additional risk to you. Taking part in this study does not
affect your normal legal rights. Whether or not you do
take part, you will retain the same legal rights as any
other patient in the NHS (which include professional in-
demnity insurance for negligence). If you wish to com-
plain about your health care or any aspects of this study,
the normal NHS mechanisms will be available to you.’
Publication
The success of the study depends entirely on the whole-
hearted collaboration of a large number of women
undergoing prolapse surgery, as well as their nurses and
physicians. For this reason, chief credit for the study will
be given, not to the committees or central organisers,
but to all those who have collaborated in the study. The
study’s publication policy is described in detail in
Additional file 3. The results of the study will be reported
first to the study collaborators. The main report will be
drafted by the PMG and circulated to all clinical collabo-
rators for comment. The final version will be agreed by
the Steering Committee before submission for publication,
on behalf of all the VUE collaborators.
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To safeguard the integrity of the main trial, reports of
explanatory or satellite studies will not be submitted for
publication without prior agreement from the PMG.
We intend to maintain interest in the study by publi-
cation of VUE newsletters at intervals for participants,
staff and collaborators. Once the main report has been
published, a lay summary of the findings will be sent in
a final VUE newsletter to all involved in the trial.
Discussion
The VUE Study is the largest-ever randomised con-
trolled trial on vault or uterine prolapse. The benefit to
women, the NHS and society is that, at the end of the
trial, it will be known which operations are most effect-
ive and cost-effective.
The main practical challenge of this trial has been par-
ticipant recruitment. Early into the recruitment period
we noted a patient preference for the Uterine Trial.
Around 70 % of those approached declined to participate,
and of these 30 % had a preference (most commonly for a
hysterectomy as opposed to uterine preservation). This
was somewhat expected but the extent of patient prefer-
ence was higher than anticipated. The main reasons for
patient preference were due to discussions with family
members/friends on their experiences, GP influence and
an assumption that removing the uterus (hysterectomy)
would ‘cure’ the prolapse. We developed a number of
strategies to improve participant recruitment, including
changes to the patient information leaflet, further site
training. We intend to publish this separately.
Trial status
The first participant was randomised into the trial on 1
May 2013, and the trial is currently open to recruitment
in 45 UK centres, with the last participant follow-up
expected in August 2017.
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